Nixon Peabody Trust Co. Sells 852 Shares of Danaher Corporation $DHR

Nixon Peabody Trust Co. cut its holdings in shares of Danaher Corporation (NYSE:DHR) by 1.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 60,863 shares of the conglomerate’s stock after selling 852 shares during the period. Nixon Peabody Trust Co.’s holdings in Danaher were worth $12,023,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Red Tortoise LLC increased its position in shares of Danaher by 175.0% during the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after buying an additional 98 shares during the period. Costello Asset Management INC bought a new position in Danaher in the 1st quarter valued at about $41,000. Ramirez Asset Management Inc. purchased a new position in shares of Danaher during the second quarter valued at approximately $40,000. Mowery & Schoenfeld Wealth Management LLC boosted its holdings in Danaher by 53.8% during the 1st quarter. Mowery & Schoenfeld Wealth Management LLC now owns 203 shares of the conglomerate’s stock worth $42,000 after acquiring an additional 71 shares during the last quarter. Finally, Strengthening Families & Communities LLC grew its position in Danaher by 81.4% in the 1st quarter. Strengthening Families & Communities LLC now owns 254 shares of the conglomerate’s stock worth $52,000 after purchasing an additional 114 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Bank of America decreased their target price on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research report on Monday, September 22nd. UBS Group decreased their price target on Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, July 23rd. Rothschild Redb lowered Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of Danaher in a report on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Eighteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $243.39.

Insider Activity at Danaher

In related news, SVP Georgeann Couchara sold 5,174 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. This represents a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 29,728 shares of company stock valued at $6,448,990 over the last 90 days. Corporate insiders own 11.20% of the company’s stock.

Danaher Stock Performance

Shares of DHR opened at $221.50 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. Danaher Corporation has a one year low of $171.00 and a one year high of $258.23. The firm has a market capitalization of $156.46 billion, a PE ratio of 45.67, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The company has a 50-day simple moving average of $205.21 and a two-hundred day simple moving average of $200.91.

Danaher (NYSE:DHR) last released its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. During the same period in the prior year, the firm earned $1.71 EPS. The company’s revenue was up 4.4% compared to the same quarter last year. On average, analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.